Online inquiry

IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ804MR)

This product GTTS-WQ804MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets LRRC15 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001135057.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 131578
UniProt ID Q8TF66
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ804MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12978MR IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PEG sTNF-RI
GTTS-WQ3273MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ART621
GTTS-WQ977MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-368
GTTS-WQ2817MR IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-301
GTTS-WQ4727MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BOS161721
GTTS-WQ2246MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ALX-0171
GTTS-WQ12021MR IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MM-302
GTTS-WQ9072MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMC-A12
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW